肺癌相关静脉血栓栓塞症的预测与风险评估进展
Advances in the Prediction and Risk Assessment of Lung Cancer-Associated Venous Thromboembolism.
作者信息
Di Wenjuan, Xu Haotian, Xue Ting, Ling Chunhua
机构信息
Department of Respiratory and Critical Care Medicine, The First Hospital Affiliated of Soochow University, Suzhou City, Jiangsu Province, People's Republic of China.
出版信息
Cancer Manag Res. 2021 Nov 4;13:8317-8327. doi: 10.2147/CMAR.S328918. eCollection 2021.
Abstract
According to the most recent data from the National Cancer Center, venous thromboembolism (VTE) has unsurprisingly become one of the most common complications in lung cancer. VTE not only interferes with the equilibrium of the clotting system but it also affects tumor progression and prognosis. For the identification of high-risk patients, many clinical risk assessment models have been developed and validated based on the risk factors found in previous studies. In this review, we will summarize advances in prediction and risk assessment of VTE, with a focus on early diagnosis and therapy, reduction of mortality, and the burden of medical costs in lung cancer patients.
摘要
根据国家癌症中心的最新数据，静脉血栓栓塞（VTE）不出所料地成为肺癌最常见的并发症之一。VTE不仅会干扰凝血系统的平衡，还会影响肿瘤进展和预后。为了识别高危患者，基于以往研究中发现的风险因素，已经开发并验证了许多临床风险评估模型。在这篇综述中，我们将总结VTE预测和风险评估方面的进展，重点关注肺癌患者的早期诊断和治疗、降低死亡率以及医疗成本负担。
相似文献
1
Advances in the Prediction and Risk Assessment of Lung Cancer-Associated Venous Thromboembolism.
Cancer Manag Res. 2021 Nov 4;13:8317-8327. doi: 10.2147/CMAR.S328918. eCollection 2021.
2
Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK).
Oncologist. 2018 Feb;23(2):247-255. doi: 10.1634/theoncologist.2017-0205. Epub 2017 Sep 26.
3
[Risk prediction of venous thromboembolism in non-small cell lung cancer patients based on COMPASS-CAT risk assessment model].
Zhonghua Zhong Liu Za Zhi. 2020 Apr 23;42(4):340-345. doi: 10.3760/cma.j.cn112152-20191101-00707.
4
Venous thromboembolism in cancer patients.
Hosp Pract (1995). 2014 Dec;42(5):24-33. doi: 10.3810/hp.2014.12.1156.
5
A systematic review of risk prediction model of venous thromboembolism for patients with lung cancer.
Thorac Cancer. 2024 Feb;15(4):277-285. doi: 10.1111/1759-7714.15219. Epub 2024 Jan 17.
6
Risk Factors and Prediction Models for Venous Thromboembolism in Ambulatory Patients with Lung Cancer.
Healthcare (Basel). 2021 Jun 21;9(6):778. doi: 10.3390/healthcare9060778.
7
Early identification of lung cancer patients with venous thromboembolism: development and validation of a risk prediction model.
Thromb J. 2023 Sep 14;21(1):95. doi: 10.1186/s12959-023-00544-w.
8
External Validation of a Venous Thromboembolic Risk Score for Cancer Outpatients with Solid Tumors: The COMPASS-CAT Venous Thromboembolism Risk Assessment Model.
Oncologist. 2020 Jul;25(7):e1083-e1090. doi: 10.1634/theoncologist.2019-0482. Epub 2020 Feb 4.
9
Models for predicting venous thromboembolism in ambulatory patients with lung cancer: a systematic review protocol.
BMJ Open. 2021 Dec 1;11(12):e055322. doi: 10.1136/bmjopen-2021-055322.
10
[Risk factors of lung cancer complicated with symptomatic venous thromboembolism].
Zhonghua Jie He He Hu Xi Za Zhi. 2016 Jun;39(6):454-8. doi: 10.3760/cma.j.issn.1001-0939.2016.06.010.
引用本文的文献
1
Machine learning-based preoperative prediction of perioperative venous thromboembolism in Chinese lung cancer patients: a retrospective cohort study.
Front Oncol. 2025 Jun 25;15:1588817. doi: 10.3389/fonc.2025.1588817. eCollection 2025.
2
Didang decoction attenuates cancer-associated thrombosis by inhibiting PAD4-dependent NET formation in lung cancer.
Pulm Circ. 2024 Oct 9;14(4):e12454. doi: 10.1002/pul2.12454. eCollection 2024 Oct.
3
Venous Thromboembolism in Burn Patients: A 5-Year Retrospective Study.
Medicina (Kaunas). 2024 Feb 2;60(2):258. doi: 10.3390/medicina60020258.
4
Lung Cancer Related Thrombosis (LCART): Focus on Immune Checkpoint Blockade.
Cancers (Basel). 2024 Jan 20;16(2):450. doi: 10.3390/cancers16020450.
5
Stratification of Risk Factors of Lung Cancer-Associated Venous Thromboembolism and Determining the Critical Point for Preemptive Intervention: A Systematic Review With Meta-analysis.
Clin Med Insights Oncol. 2023 Jun 28;17:11795549231175221. doi: 10.1177/11795549231175221. eCollection 2023.
6
Could PD-L1 positivity be associated with venous thrombosis in patients with non-small cell lung cancer?
J Thromb Thrombolysis. 2023 Feb;55(2):382-391. doi: 10.1007/s11239-022-02753-y. Epub 2022 Dec 24.
7
Derivation, validation and assessment of a novel nomogram-based risk assessment model for venous thromboembolism in hospitalized patients with lung cancer: A retrospective case control study.
Front Oncol. 2022 Oct 10;12:988287. doi: 10.3389/fonc.2022.988287. eCollection 2022.
8
Development and validation of a nomogram to assess postoperative venous thromboembolism risk in patients with stage IA non-small cell lung cancer.
Cancer Med. 2023 Jan;12(2):1217-1227. doi: 10.1002/cam4.4982. Epub 2022 Jun 27.
本文引用的文献
1
Cancer incidence and mortality in China, 2015.
J Natl Cancer Cent. 2020 Dec 17;1(1):2-11. doi: 10.1016/j.jncc.2020.12.001. eCollection 2021 Mar.
2
Venous Thromboembolism in Patents With Lung Cancer.
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620977910. doi: 10.1177/1076029620977910.
3
Clinical practice guidelines for the treatment and prevention of cancer-associated thrombosis.
Thromb Res. 2020 Jul;191 Suppl 1:S79-S84. doi: 10.1016/S0049-3848(20)30402-3.
4
Impact of Tumor Genomic Mutations on Thrombotic Risk in Cancer Patients.
Cancers (Basel). 2020 Jul 19;12(7):1958. doi: 10.3390/cancers12071958.
5
Risk Factors and Clinical Significance of D-Dimer in the Development of Postoperative Venous Thrombosis in Patients with Lung Tumor.
Cancer Manag Res. 2020 Jun 30;12:5169-5179. doi: 10.2147/CMAR.S256484. eCollection 2020.
6
Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm.
Cancers (Basel). 2020 May 2;12(5):1144. doi: 10.3390/cancers12051144.
7
From Classical Laboratory Parameters to Novel Biomarkers for the Diagnosis of Venous Thrombosis.
Int J Mol Sci. 2020 Mar 11;21(6):1920. doi: 10.3390/ijms21061920.
8
Potential Mechanisms of Cancer-Related Hypercoagulability.
Cancers (Basel). 2020 Feb 29;12(3):566. doi: 10.3390/cancers12030566.
9
ONKOTEV Score as a Predictive Tool for Thromboembolic Events in Pancreatic Cancer-A Retrospective Analysis.
Oncologist. 2020 Feb;25(2):e284-e290. doi: 10.1634/theoncologist.2019-0510. Epub 2019 Oct 22.
10
Are direct oral anticoagulants an economically attractive alternative to low molecular weight heparins in lung cancer associated venous thromboembolism management?
J Thromb Thrombolysis. 2020 Oct;50(3):642-651. doi: 10.1007/s11239-020-02047-1.
Zotero 插件